Log in

  • Home
  • ODS Monthly Meeting

ODS Monthly Meeting

  • 09/08/2021
  • 1:00 PM - 5:00 PM
  • Virtual


Registration is closed

Featured Speaker: Seemal Desai, MD, FAAD - Clinical Assistant Professor of Dermatology at University of Texas

1:00-2:00 - What's New in Skin of Color - Seemal Desai, MD, FAAD
2:00-3:00 - JAK/TYK2 Inhibition: New Frontiers in the Treatment of Psoriasis - Seemal Desai, MD, FAAD - Please Complete Pre-Test
3:00-3:15 - Break
3:15-3:30 - Resident Lecture - Emma Hill, MD
3:30-3:45 - Resident Lecture - Vesicles and Pustules in an Infant - Alison Triester, MD
3:45-4:00 - OHSU/ODS Updates
4:00-5:00 - Patient Case Discussion (register a case below)

Register a Patient for Case Discussion


  • Members: FREE (Login to register)


Seemal R. Desai, MD, FAAD
Clinical Assistant Professor
Department of Dermatology
University of Texas Southwestern Medical Center
Dallas, TX

This activity is provided by the University of Cincinnati. 
Paradigm Medical Communications, LLC is the educational partner.  

Disclosure of Commercial Support
This activity is supported by an educational grant from Bristol-Myers Squibb.

Target Audience
This activity has been designed to address the educational needs of dermatology clinicians. It may also be of benefit to rheumatology and primary care clinicians, as well as other healthcare providers involved with or interested in the management of patients with psoriasis.

Statement of Need
Psoriasis is a common autoimmune disorder with associated comorbidities that are more than skin deep. Patients with psoriasis are at increased risk for cardiovascular and metabolic disease, malignancies, and anxiety/depression. This activity will provide clinicians with a solid foundation for understanding the pathophysiology of psoriasis along with other autoimmune diseases, how this pathophysiology informs treatment options, and the most recent clinical trial data for current and emerging agents and management recommendations available to guide therapy selection.

Learning Objectives
Upon proper completion of this activity, participants should be better able to:

  • Identify the JAK/TYK2-STAT–mediated pathways involved in the pathophysiology of psoriasis 
  • Summarize evidence for the efficacy, safety, and mechanisms of action for new and emerging agents in psoriasis, and the implications for treatment
  • Apply current research findings and recommendations to the treatment of psoriasis and comorbidities 


  • Pathophysiology of Psoriasis
  • JAK/TYK2 Inhibitors in Psoriasis Data 
  • Psoriasis Treatment Guidelines
  • New Directions in Psoriasis Therapy: The Role of Emerging JAK/TYK2 Inhibitors in Psoriasis

Physician Accreditation Statement
The University of Cincinnati is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

In accordance with ACCME requirements on disclosure, faculty and contributors are asked to disclose any relationships with commercial interests associated with the area of medicine featured in the activity. These relationships are described below.

Seemal R. Desai, MD, FAAD
Consulting Fees: Bristol-Myers Squibb Company; Pfizer Inc
Speakers Bureau: Pfizer Inc

About ODS

ODS is a non-profit organization with a mission to continually improve dermatologic care through education, advocacy, and service. We represent nearly 300 dermatologists, physicians assistants, and nurse practitioners in Oregon and the region.

Contact Us

Copyright © Oregon Dermatology Society
Powered by Wild Apricot Membership Software